(Q37179739)

18 August 2017

Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines (English)

1 reference

18 August 2017

0 references

1 reference

K Shimizu

1

1 reference

18 August 2017

R C Fields

series ordinal

2

1 reference

18 August 2017

M Giedlin

series ordinal

3

1 reference

18 August 2017

J J Mulé

series ordinal

4

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 March 1999

1 reference

Proceedings of the National Academy of Sciences of the United States of America

18 August 2017

1 reference

18 August 2017

96

1 reference

18 August 2017

2268-2273

1 reference

18 August 2017

5

1 reference

Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=26772

Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=26772

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=26772

Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=26772

Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=26772

Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factor

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=26772

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=26772

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=26772

The dendritic cell system and its role in immunogenicity

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=26772

Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=26772

Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=26772

Immunotherapy with low-dose interleukin-2: rationale for prevention of immune-deficiency-associated cancer.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=26772

Interleukin-2 therapy after bone marrow or stem cell transplantation for hematologic malignancies

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=26772

Dendritic cells as adjuvants for immune-mediated resistance to tumors

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=26772

Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=26772

Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=26772

Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=26772

Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=26772

Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells.

26 June 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.96.5.2268

Dendritic cells: unique leukocyte populations which control the primary immune response

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=26772

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

3 September 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.96.5.2268

DNA-based immunization by in vivo transfection of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.96.5.2268

Biological Activity of Recombinant Human Interleukin-2 Produced inEscherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.96.5.2268

Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.96.5.2268

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.96.5.2268

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.96.5.2268

In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells

21 January 2018

1 reference

12 December 2020

Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2

1 reference

12 December 2020

High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings

1 reference

12 December 2020

Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2

1 reference

12 December 2020

Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice

1 reference

12 December 2020

CD4+ T-cells from mice immunized to syngeneic sarcomas recognize distinct, non-shared tumor antigens

1 reference

12 December 2020

Induction of antitumor immunity using bone marrow-generated dendritic cells

1 reference

12 December 2020

Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy

1 reference

12 December 2020

The role of tumor necrosis factor alpha in modulating the quantity of peripheral blood-derived, cytokine-driven human dendritic cells and its role in enhancing the quality of dendritic cell function in presenting soluble antigens to CD4+ T cells in

1 reference

12 December 2020

Identifiers

DOI

10.1073/PNAS.96.5.2268

1 reference

18 August 2017

0 references

1 reference

18 August 2017

1 reference